@FiercePharma: Japan OKs Novo Nordisk's long-acting insulin Tresiba, still awaiting decision from FDA. More | Follow @FiercePharma
> Aveo Oncology and Japanese drug developer Astellas Pharma say Aveo has submitted a new drug application to the FDA for approval of tivozanib to treat kidney cancer. Story
> Vectura announced that Japan has approved its Seebri inhalation capsules used in inhaler devices and says they will be on the market there by the end of the year. Item
> South Africa's Medicines Control Council (MCC) has denied compassionate access to a TB drug that for many drug-resistant patients is their last hope. Story
> New Jersey has secured $2.6 million in federal grants to help laid off pharma workers get retrained and find new jobs, an announcement that follows Roche's ($RHHBY) decision to close an R&D center there. Story
Biotech News
@FierceBiotech: The French government wants Sanofi 'guarantees' on the future of Toulouse R&D. More | Follow @FierceBiotech
@JohnCFierce: Paratek - Ph3 antibiotic, lost a big Novartis deal last year - wants a $92M IPO? Hmmmm. More | Follow @JohnCFierce
@RyanMFierce: A crisis of credentials? Abbott came clean that choice to lead pharma unit didn't finish college. More | Follow @RyanMFierce
> IPO priced for biotech working on drug against chin fat. Story
> Novo Nordisk scuttles late-stage hemophilia drug over patient risk. Article
@FierceMedDev: Boston Scientific won a CE mark for a Deep brain stimulation treatment of Parkinson's disease. More | Follow @FierceMedDev
@MarkHFierce: Finally--the deal is done. Sony is officially investing $645M into Olympus and the two will partner on medical equipment. More | Follow @MarkHFierce
@DamianFierce: The FDA is getting an earful from lawmakers over the hackability of medical devices. More | Follow @DamianFierce
> Medtronic makes a splash in China with $816M Kanghui buyout. Story
> A giant step forward for dissolvable medical devices. News
> Olympus, Sony ally on endoscope, med device development. Article
And Finally... Kythera Biopharmaceuticals is seeking $14 to $16 per share in its IPO to raise money to continue its development of an injected drug for elective treatments to wipe out chin fat. Story